Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brieux Chardès

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Antiviral Research|August 13, 2022
Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytesManon Desmares, Marion Delphin, Brieux Chardès, et al.
Frontiers in Medicine|January 23, 2025
Characteristics and outcomes of patients with LAM receiving sirolimus in France based on real-life dataVincent Cottin, Antoine Cases, Virginie Bourdin, et al.
JHEP Reports : Innovation in Hepatology|February 10, 2022
Inducers of the NF-κB pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity <i>in vitro</i>Maud Michelet, Dulce Alfaiate, Brieux Chardès, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Antiviral Research|August 13, 2022
Insights on the antiviral mechanisms of action of the TLR1/2 agonist Pam3CSK4 in hepatitis B virus (HBV)-infected hepatocytesManon Desmares, Marion Delphin, Brieux Chardès, et al.
Frontiers in Medicine|January 23, 2025
Characteristics and outcomes of patients with LAM receiving sirolimus in France based on real-life dataVincent Cottin, Antoine Cases, Virginie Bourdin, et al.
JHEP Reports : Innovation in Hepatology|February 10, 2022
Inducers of the NF-κB pathways impair hepatitis delta virus replication and strongly decrease progeny infectivity <i>in vitro</i>Maud Michelet, Dulce Alfaiate, Brieux Chardès, et al.
Pageof 1